CE Mark for Boston Scientific's Eluvia Peripheral Stent

Boston Scientific (NYSE: BSX) announced this morning that its Eluvia™ Drug-Eluting Vascular Stent has received the CE Mark for use in treating peripheral artery disease in the superficial femoral and proximal popliteal arteries. The company states that the Eluvia is the first polymer-based DES approved in Europe for use in the peripheral arteries.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news